DEFA14A: ABVC BioPharma Amends Proxy Statement for Annual Meeting, Seeks Approval for Increased Share Issuance

ABVC BioPharma updates its proxy statement to include shares from a recent private transaction with Lind and clarifies quorum requirements for its upcoming annual meeting.

Summary

• ABVC BioPharma has amended its proxy statement for the annual meeting of stockholders to be held on April 16, 2024.
• The amendment includes an expansion of Proposal 3 to include shares issuable pursuant to a private transaction with Lind Global Fund II, LP, closed on January 17, 2024.
• The amendment also clarifies the quorum required for the annual meeting, reducing it from a majority to thirty third and one-third (33 1/3%) of the outstanding voting securities.
• The proxy statement now includes the Annual Report on Form 10-K for the year ended December 31, 2023.
• As of the record date of March 8, 2024, there were 10,560,421 shares of Common Stock outstanding and entitled to vote.
• Proposal 3 seeks authorization for the issuance of shares underlying convertible notes and warrants issued to Lind Global Fund II, LP, exceeding 20% of the outstanding common stock.
• The company entered into securities purchase agreements with Lind on November 17, 2023, and January 17, 2024, issuing secured, convertible notes and warrants.
• The November note was for $1,200,000, and the January note was for $1,000,000.
• The notes are convertible into shares of common stock at a conversion price that is the lesser of $3.50 or 90% of the average of the three lowest VWAPs during the 20 trading days prior to conversion.
• Lind also received warrants to purchase up to 1,000,000 shares of common stock at an initial exercise price of $2 per share for each offering.
• In February 2024, the conversion price of both notes was amended to have a floor price of $1.00.
• As of December 31, 2023, the company's cash and cash equivalents were approximately $60,155.
• The board determined it was necessary to raise additional funds for general corporate purposes through the Lind Offerings, which yielded gross proceeds of $2.2 million.
• The company is seeking stockholder approval under Nasdaq Listing Rule 5635(d) for the potential issuance of common stock in excess of 2,732,102 shares, which is 20% of the total number of shares of Common Stock outstanding immediately prior to the execution of each of the SPAs.
• Failure to obtain shareholder approval could result in an Event of Default under the Lind Notes, requiring the company to pay Lind an amount equal to 120% of the then outstanding principal amount of the Lind Notes.

Sentiment

Score: 4

Explanation: The document highlights the company's need for additional funding and the potential for significant dilution, which is concerning. However, the company is taking steps to address its financial challenges and continue its operations.

Positives

• The company secured $2.2 million in gross proceeds through the Lind Offerings.
• The board considered numerous alternatives to the transaction, none of which proved to be feasible or would have resulted in aggregate terms equivalent to, or more favorable than, the terms obtained in the Lind Offerings.

Negatives

• The company had very limited cash and cash equivalents of approximately $60,155 as of December 31, 2023.
• The potential issuance of shares could significantly dilute current stockholders' ownership.
• Failure to obtain shareholder approval for the increased issuance proposal could trigger an event of default under the Lind Notes, requiring a significant payment to Lind.

Risks

• The potential issuance of shares could significantly dilute current stockholders' ownership.
• The issuance or resale of common stock issued to Lind could cause the market price of the company's common stock to decline.
• The increased number of issued shares may have an incidental anti-takeover effect.
• Failure to obtain shareholder approval for the increased issuance proposal could trigger an event of default under the Lind Notes, requiring a significant payment to Lind.

Future Outlook

The company will call a meeting every four months thereafter to seek shareholder approval until the date the shareholders approve this Proposal 3.

Industry Context

This announcement reflects the ongoing challenges faced by small biopharmaceutical companies in securing funding and navigating regulatory requirements. The reliance on private transactions with firms like Lind Global Fund II, LP, is a common strategy for companies with limited access to traditional capital markets.

Comparison to Industry Standards

• The terms of the Lind financing, including the anti-dilution provisions and warrant coverage, are relatively standard for small-cap biotech companies seeking capital.
• Comparable companies such as XOMA Corporation and Catalyst Biosciences have also utilized similar financing structures to fund their operations.
• However, the high cost of capital associated with these types of financings can be a significant burden for companies with limited revenue.

Corporate Governance

Stakeholder Impact

• Shareholders face potential dilution of their ownership if the increased issuance proposal is approved.
• The company's ability to continue its operations and develop its product pipeline depends on securing additional funding.
• Employees' jobs may be at risk if the company is unable to secure additional funding.

Next Steps

• Stockholders must submit their vote on all four proposals being considered at the Annual Meeting by one of the alternatives described in the Proxy Statement.
• The company will hold its Annual Meeting of Stockholders on April 16, 2024.
• The company will continue to seek shareholder approval for the increased issuance proposal.

Key Dates

Keywords

shareholder approval, convertible notes, warrants, Lind Global Fund II, share issuance, quorum, proxy statement, ABVC BioPharma